Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
December 2003
in “
Clinical breast cancer
”
Studysummary The authors concluded that pegylated liposomal doxorubicin may offer comparable efficacy to conventional doxorubicin with reduced toxicity in metastatic breast cancer treatment.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on clinical-breast-cancer.com →